MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

MDT

83.06

+0.24%↑

VEEV

213.48

-0.09%↓

A

103.34

+2.82%↑

HQY

80.25

+4.9%↑

PDCO

30.85

-0.29%↓

Search

Alcon Inc

Chiusa

SettoreSettore sanitario

82.47 -1.55

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

80.42

Massimo

84.79

Metriche Chiave

By Trading Economics

Entrata

21M

284M

Vendite

48M

2.5B

P/E

Media del settore

46.307

63.778

EPS

0.72

Rendimento da dividendi

0.28

Margine di Profitto

11.351

Dipendenti

25,599

EBITDA

56M

397M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+30.21% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.28%

2.39%

Utili prossimi

13 mag 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

5.9B

47B

Apertura precedente

84.02

Chiusura precedente

82.47

Notizie sul Sentiment di mercato

By Acuity

50%

50%

133 / 386 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Very Strong Bearish Evidence

Alcon Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

26 mar 2025, 21:22 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Buys Majority Stake in Aurion to Advance Eye Disease Treatment

24 mar 2025, 12:36 UTC

Acquisizioni, Fusioni, Takeovers

Alcon to Buy Lensar in Deal Worth Up to $430 Million

12 nov 2024, 18:48 UTC

Utili
I principali Market Mover

Alcon Posts Higher 3Q Sales and Profit, Lowers 2024 Sales View

26 mar 2025, 21:55 UTC

Discorsi di Mercato
Acquisizioni, Fusioni, Takeovers

Alcon Deal for Aurion Follows 2022 Investment, 2024 Lawsuit -- Market Talk

26 mar 2025, 20:33 UTC

Acquisizioni, Fusioni, Takeovers

Aurion Board Appoints Arnaud Lacoste as CEO of Aurion

26 mar 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Aurion Will Operate as a Separate Company With Full Support From Alcon to Advance Its Clinical-Stage Allogeneic Cell Therapy Asset

26 mar 2025, 20:32 UTC

Acquisizioni, Fusioni, Takeovers

Leverages Alcon's Global Scale With Aurion's Cell Therapy Expertise to Accelerate U.S. Phase 3 Development in Fall of 2025 >ALC.EB

26 mar 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Acquires Interest in Aurion to Advance Innovative Cell Therapy for Corneal Endothelial Disease >ALC.EB

26 mar 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Inc. Unit Alcon Research Previously Sued Aurion to Prevent It From Going Public

26 mar 2025, 20:31 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Acquires Majority Interest in Aurion Biotech >ALC.EB

26 mar 2025, 20:30 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Acquires Majority Interest in Aurion Biotech

24 mar 2025, 12:21 UTC

Acquisizioni, Fusioni, Takeovers

Alcon to Buy Lensar in Deal Worth Up to $430M

24 mar 2025, 12:05 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Transaction Is Anticipated to Close in Mid-To-Late 2025 >ALC

24 mar 2025, 12:05 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Transaction Represents a Total Consideration of Up to About $430M >ALC

24 mar 2025, 12:04 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Additional Non-Tradeable Contingent Value Right Offering Up to $2.75 Per Shr in Cash, Conditioned on Achievement of 614,000 Cumulative Procedures With LENSAR's Products Between Jan 1, 2026, and Dec 31, 2027 >ALC

24 mar 2025, 12:04 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Will Purchase All Outstanding Shrs of LENSAR for $14.00 Per Shr in Cash >ALC

24 mar 2025, 12:03 UTC

Acquisizioni, Fusioni, Takeovers

Alcon: Acquisition Includes ALLY Robotic Cataract Laser Treatment System, LENSAR's Proprietary Streamline Software Technology and LENSAR Legacy Laser System >ALC

24 mar 2025, 12:03 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Agrees to Acquire LENSAR >ALC

24 mar 2025, 12:00 UTC

Acquisizioni, Fusioni, Takeovers

Alcon Agrees To Acquire LENSAR, Inc. >ALC LNSR

25 feb 2025, 21:33 UTC

Utili

Alcon Sees 2025 Adj EPS $3.15-Adj EPS $3.25 >ALC.EB

25 feb 2025, 21:33 UTC

Utili

Alcon Sees 2025 Sales $10.2B-$10.4B >ALC.EB

25 feb 2025, 21:32 UTC

Utili

Alcon: Board Authorized the Repurchase of Up to $750M of the Company's Common Shrs >ALC.EB

25 feb 2025, 21:31 UTC

Utili

Alcon 4Q EPS 57c >ALC.EB

25 feb 2025, 21:31 UTC

Utili

Alcon 4Q Rev $2.5B >ALC.EB

17 dic 2024, 15:05 UTC

Discorsi di Mercato

Alcon's Late-Stage Pipeline Set To Drive Revenue Growth Next Year -- Market Talk

12 nov 2024, 17:38 UTC

Utili

Alcon Narrows 2024 View To Adj EPS $3.00-Adj EPS $3.05 >ALC

12 nov 2024, 17:38 UTC

Utili

Alcon Had Seen 2024 Sales $9.9B-$10.1B >ALC

12 nov 2024, 17:37 UTC

Utili

Alcon Cuts 2024 View To Sales $9.8B-$9.9B >ALC

12 nov 2024, 17:36 UTC

Utili

Alcon 3Q Core Operating Margin 20.6% >ALC

12 nov 2024, 17:36 UTC

Utili

Alcon 3Q Sales $2.43B >ALC

Confronto tra pari

Modifica del prezzo

Alcon Inc Previsione

Obiettivo di Prezzo

By TipRanks

30.21% in crescita

Previsioni per 12 mesi

Media 109.14 USD  30.21%

Alto 120 USD

Basso 90 USD

Basato su 20 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Alcon Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

20 ratings

18

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

N/A / 92.61Supporto e resistenza

A breve termine

Very Strong Bearish Evidence

A termine intermedio

Very Strong Bearish Evidence

A lungo termine

Bearish Evidence

Sentiment

By Acuity

133 / 386 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Neutral

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Alcon Inc

Alcon Inc. researches, develops, manufactures, distributes, and sells eye care products for eye care professionals and their patients worldwide. The company's Surgical segment offers equipment, instrumentation and diagnostics, intraocular lenses (IOLs), and other implantables; and consumables, including viscoelastics, surgical solutions, incisional instruments, surgical custom packs, and other products for surgical procedures. Its cataract products include Centurion vision system, LenSx laser system, ARGOS biometer, LuxOR surgical ophthalmic microscope, SMARTCATARACT health platform, NGENUITY 3D visualization system, Verion reference unit and Verion digital marker, and ORA system for intra-operative measurements; custom pak surgical procedure packs; vitreoretinal products comprising constellation vision systems, procedure packs, lasers and hand-held microsurgical instruments, and grieshaber and MIVS instruments, as well as scissors, forceps and micro-instruments, medical grade vitreous tamponades, and Hypervit vitrectomy probes; refractive surgery products, including WaveLight lasers and Contoura Vision used for LASIK treatment; EX-PRESS glaucoma filtration device; and implantable products, including AcrySof IQ products, such as monofocal IOLs and advanced technology IOLs for the correction of presbyopia and astigmatism at the time of cataract surgery. Its Vision Care segment provides daily disposable, reusable, and color-enhancing contact lenses; ocular health products, such as dry eye, glaucoma, contact lens care, and ocular allergies; and ocular vitamins and redness relievers. The company was formerly known as Alcon Universal S.A. and changed its name to Alcon Inc. in December 2001. Alcon Inc. was founded in 1945 and is headquartered in Geneva, Switzerland.